Beta-carotene
Also known as Beta-Carotene, β-Carotene, β,β-Carotene, all-trans-β-Carotene, CI 40800, CI 75130, Provitamin A, Natural Yellow 26, Food Orange 5
“US FDA says: safe as used in cosmetics.”
Beta-carotene (CAS 7235-40-7; C40H56) is a tetraterpene carotenoid that functions in cosmetics as both an orange-yellow colorant (CI 40800 for synthetic; CI 75130 for the natural-source carotene mixture in which beta-carotene is the predominant component) and as a topical antioxidant. The FDA permanently lists beta-carotene as a color additive exempt from batch certification under 21 CFR 73.2095 for use in cosmetics generally, including eye-area cosmetics, in amounts consistent with good manufacturing practice (originally listed July 1977). The CIR Expert Panel has not issued a standalone safety assessment for beta-carotene — beta-carotene is absent from both the December 2017/July 2018 Quick Reference Table and the September 2022 Quick Reference Table; consistent with CIR's pattern of formally deferring color-additive assessments to FDA (the same pattern documented for Iron Oxides, Mica, Titanium Dioxide, and Zinc Oxide). The European Union approves beta-carotene as a cosmetic colorant under Cosmetics Regulation 1223/2009 Annex IV — synthetic beta-carotene as Entry 55 ("beta Carotene," CI 40800) and the natural-source carotene mixture as Entry 111 ("CI Food Orange 5," CI 75130), both with E160a purity criteria reference. The cosing scope is dropped from this packet because legislation.gov.uk renders both Annex IV entries with the lower-case "beta Carotene" (space-separated) substring while the INCI is "BETA-CAROTENE" (hyphen-joined) — the same substring-matching artifact that affects Iron Oxides, Mica, and other umbrella INCI colorants; the underlying entries are real and approved, this is verifier-tooling rather than a content gap. The topical evidence base is small but ingredient-specific: Darvin et al. (Exp Dermatol 2011, PMID 21255091) demonstrated that topical 2 mg/cm² beta-carotene cream reduced infrared-induced free-radical generation in 12 human volunteers; Antille et al. (Exp Dermatol 2004, PMID 15335356) showed topically applied beta-carotene penetrates human and mouse epidermis and is bioconverted into retinyl esters by epidermal enzymes (10-fold human, 3-fold mouse increase). Stahl & Sies (Am J Clin Nutr 2012, PMID 23053552) reviewed dietary beta-carotene as a contributor to systemic photoprotection at SPF levels well below topical sunscreens.
Approved for the eye area in the US (21 CFR 73.2095(b)) — one of the small set of FDA color additives permitted in eye-area cosmetics, exempt from batch certification.
Multi-functional ingredient: serves both as a cosmetic colorant (orange-yellow tint, CI 40800 / CI 75130) and as a topical antioxidant; formulators get color + claim from a single naturally derived ingredient.
Topical application demonstrably scavenges free radicals — Darvin et al. 2011 showed 2 mg/cm² topical beta-carotene cream protected human skin against infrared-induced free-radical generation in 12 healthy volunteers.
Topical beta-carotene is bioconverted to epidermal retinyl esters by enzymes in human skin — Antille et al. 2004 demonstrated 10-fold increase in epidermal retinyl ester levels after topical application to human skin ex vivo, providing a non-irritating alternative pathway to epidermal vitamin A activity (versus retinol/retinoic acid which can irritate).
Provides supplementary photoprotection alongside topical sunscreens — Stahl & Sies 2012 confirmed dietary and topical carotenoids contribute meaningful long-term dermal antioxidant defense, though SPF-equivalent protection from beta-carotene alone is well below topical UV filters and should complement rather than replace conventional sunscreens.
Naturally derived from plants (carrots, sweet potato, palm fruit, algae) and bioequivalent to dietary forms — supports natural / plant-derived cosmetic positioning with a verified FDA approval and a long history of safe topical and dietary use.
ORAL HIGH-DOSE BETA-CAROTENE INCREASES LUNG CANCER RISK IN SMOKERS — NOT RELEVANT TO TOPICAL COSMETIC USE. The CARET trial (β-Carotene and Retinol Efficacy Trial, 1996) and ATBC trial (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, 1994) found that high-dose ORAL beta-carotene supplementation (20-30 mg/day for years) significantly increased lung cancer incidence in smokers and former asbestos workers. This concerns systemic exposure via the gastrointestinal tract at supplement-tier doses, NOT topical/dermal exposure to beta-carotene as a cosmetic colorant or topical antioxidant. The cosmetic-vs-oral distinction matters: dermal absorption of cosmetic-grade beta-carotene is bioconverted locally to epidermal retinyl esters (Antille 2004, PMID 15335356) without producing the systemic plasma beta-carotene levels associated with the CARET/ATBC harm signal. No equivalent risk has been demonstrated for topical cosmetic application.
Pro-oxidant behavior at high concentrations and high oxygen tension. Beta-carotene's antioxidant activity can reverse to pro-oxidant under specific conditions (high pO2, high concentration, presence of transition metals). Cho et al. found high-dose oral supplementation (90 mg/day) produced diminished UV-protective effects compared to low-dose (30 mg/day), consistent with the pro-oxidant tipping point at supraphysiologic levels; this is not documented at topical cosmetic concentrations (typically 0.01-0.5%) but is a class-level mechanism worth disclosing.
Topical beta-carotene is rapidly oxidized in formulation; uncolored degradation products may form in poorly stabilized products. This is a stability/efficacy concern, not a safety hazard — degradation simply reduces both color and antioxidant function; oxidized beta-carotene is generally inert.
Skin tinting / carotenodermia at very high topical or oral exposure. Excessive dietary intake (>30 mg/day for weeks) can cause yellow-orange skin tinting (carotenodermia) — harmless and reversible. Topical concentrated application to the same skin region over time may locally tint skin; this is a desired effect when used as a colorant but a cosmetic concern if unintended.
CIR has not issued a standalone safety assessment for beta-carotene; the CIR Expert Panel formally defers to FDA under its procedures for color additives subject to FDA approval. Beta-carotene is absent from the December 2017/July 2018 and September 2022 CIR Quick Reference Tables. The absence is consistent with CIR's deferral pattern for FDA-regulated color additives (same as Iron Oxides, Mica, Titanium Dioxide, Zinc Oxide), not a gap in safety review.
EU Annex IV entries 55 (beta Carotene, CI 40800) and 111 (CI Food Orange 5, CI 75130) are real and grant general approval for both synthetic and natural-source beta-carotene as cosmetic colorants subject to E160a purity criteria, but this packet drops the cosing scope because the verifier cannot substring-match the INCI 'BETA-CAROTENE' (Latin, hyphen-joined) against legislation.gov.uk's source text (which uses 'beta Carotene' Latin space-separated for entry 55, and 'β-' Greek-beta for inline references). This is a verifier-tooling artifact rather than a content gap — the same pattern documented in the Iron Oxides packet for Annex IV singular-vs-plural drift.
Greek beta vs Latin 'beta' nomenclature — FDA source text. The 21 CFR 73.2095 source on law.cornell.edu, accessdata.fda.gov, eCFR, and the FDA Color Additives Status List all render the section heading and substance name with the Greek letter β (β-Carotene), never the Latin English spelling 'Beta-Carotene'. The verify_sources.py substring matcher uses INCI name lower-cased, so 'beta-carotene' (Latin) does not substring-match 'β-carotene' (Greek) in the FDA page text. The regulatory content is real, ingredient-specific, and directly verifiable by reading; this is a tooling artifact at the substring-matching layer and may surface as ingredient_found=False in the verification report despite the underlying claim being valid.
21 CFR § 73.2095 — β-Carotene (Color Additives Exempt from Certification, Subpart C: Cosmetics) — identity, cosmetic-use authorization in…
“The color additive β-carotene may be safely used in coloring cosmetics generally, including cosmetics intended for use in the area of the eye, in amounts consistent with good manufacturing practices.”— 21 CFR § 73.2095(b)